Epigenetic silencing of MEIS2 in prostate cancer recurrence

BACKGROUND: Current diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, resulting in overdiagnosis and overtreatment of clinically insignificant tumors. Thus, to improve the management of PC, novel biomarkers are urgently needed. RESULTS: In this study, we integrated genome-wide...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Epigenetics
Autors principals: Nørgaard, Maibritt, Haldrup, Christa, Bjerre, Marianne Trier, Høyer, Søren, Ulhøi, Benedicte, Borre, Michael, Sørensen, Karina D.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6805635/
https://ncbi.nlm.nih.gov/pubmed/31640805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-019-0742-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars